Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 6164 | 3.06 |
09:34 ET | 22293 | 3.055 |
09:36 ET | 25643 | 3.0791 |
09:38 ET | 34803 | 3.11 |
09:39 ET | 38810 | 3.145 |
09:41 ET | 45092 | 3.145 |
09:43 ET | 24375 | 3.145 |
09:45 ET | 17568 | 3.14 |
09:48 ET | 27054 | 3.12 |
09:50 ET | 21264 | 3.135 |
09:52 ET | 26693 | 3.125 |
09:54 ET | 14608 | 3.1189 |
09:56 ET | 15437 | 3.1599 |
09:57 ET | 38214 | 3.175 |
09:59 ET | 17173 | 3.175 |
10:01 ET | 15676 | 3.155 |
10:03 ET | 24995 | 3.13 |
10:06 ET | 16242 | 3.12 |
10:08 ET | 51732 | 3.0806 |
10:10 ET | 17395 | 3.1 |
10:12 ET | 10864 | 3.12 |
10:14 ET | 9023 | 3.105 |
10:15 ET | 8109 | 3.1 |
10:17 ET | 24205 | 3.1 |
10:19 ET | 15009 | 3.095 |
10:21 ET | 1807 | 3.0982 |
10:24 ET | 4230 | 3.095 |
10:26 ET | 22083 | 3.105 |
10:28 ET | 36467 | 3.125 |
10:30 ET | 10482 | 3.1198 |
10:32 ET | 8818 | 3.1 |
10:33 ET | 5184 | 3.09 |
10:35 ET | 5700 | 3.08 |
10:37 ET | 15778 | 3.095 |
10:39 ET | 7713 | 3.0899 |
10:42 ET | 8837 | 3.1 |
10:44 ET | 12840 | 3.1 |
10:46 ET | 9498 | 3.11 |
10:48 ET | 6796 | 3.105 |
10:50 ET | 16734 | 3.115 |
10:51 ET | 3433 | 3.115 |
10:53 ET | 15774 | 3.115 |
10:55 ET | 2492 | 3.115 |
10:57 ET | 12705 | 3.105 |
11:00 ET | 5112 | 3.105 |
11:02 ET | 12763 | 3.095 |
11:04 ET | 7278 | 3.105 |
11:06 ET | 621 | 3.1 |
11:08 ET | 4904 | 3.105 |
11:09 ET | 9899 | 3.1 |
11:11 ET | 5614 | 3.085 |
11:13 ET | 19816 | 3.1 |
11:15 ET | 5684 | 3.105 |
11:18 ET | 8231 | 3.1 |
11:20 ET | 1000 | 3.1 |
11:22 ET | 2762 | 3.1061 |
11:24 ET | 5307 | 3.105 |
11:26 ET | 1630 | 3.105 |
11:27 ET | 19495 | 3.12 |
11:29 ET | 3100 | 3.115 |
11:31 ET | 9910 | 3.115 |
11:33 ET | 3155 | 3.115 |
11:36 ET | 9957 | 3.115 |
11:38 ET | 8824 | 3.11 |
11:40 ET | 29476 | 3.1145 |
11:42 ET | 3941 | 3.115 |
11:44 ET | 2250 | 3.115 |
11:45 ET | 11131 | 3.115 |
11:47 ET | 1500 | 3.115 |
11:49 ET | 6250 | 3.115 |
11:51 ET | 4097 | 3.115 |
11:54 ET | 8366 | 3.115 |
11:56 ET | 25288 | 3.15 |
11:58 ET | 19407 | 3.155 |
12:00 ET | 5727 | 3.145 |
12:02 ET | 12603 | 3.145 |
12:03 ET | 19110 | 3.15 |
12:05 ET | 2111 | 3.155 |
12:07 ET | 1611 | 3.155 |
12:09 ET | 10204 | 3.145 |
12:12 ET | 1900 | 3.1499 |
12:14 ET | 1500 | 3.145 |
12:16 ET | 10140 | 3.15 |
12:18 ET | 1851 | 3.15 |
12:20 ET | 9616 | 3.155 |
12:21 ET | 36333 | 3.16 |
12:23 ET | 9349 | 3.175 |
12:25 ET | 12897 | 3.175 |
12:27 ET | 26964 | 3.175 |
12:30 ET | 498 | 3.175 |
12:32 ET | 2683 | 3.175 |
12:34 ET | 2260 | 3.18 |
12:36 ET | 1803 | 3.175 |
12:38 ET | 11011 | 3.185 |
12:39 ET | 2235 | 3.1899 |
12:41 ET | 17911 | 3.185 |
12:43 ET | 2600 | 3.185 |
12:45 ET | 2546 | 3.185 |
12:48 ET | 600 | 3.185 |
12:50 ET | 7308 | 3.195 |
12:52 ET | 6781 | 3.21 |
12:54 ET | 1800 | 3.21 |
12:56 ET | 4031 | 3.205 |
12:57 ET | 40544 | 3.175 |
12:59 ET | 700 | 3.175 |
01:01 ET | 10170 | 3.16 |
01:03 ET | 3700 | 3.165 |
01:06 ET | 800 | 3.16 |
01:08 ET | 15248 | 3.175 |
01:10 ET | 8757 | 3.18 |
01:12 ET | 8123 | 3.195 |
01:14 ET | 1562 | 3.195 |
01:15 ET | 3339 | 3.19 |
01:17 ET | 900 | 3.195 |
01:19 ET | 3207 | 3.195 |
01:21 ET | 3823 | 3.195 |
01:24 ET | 48530 | 3.195 |
01:26 ET | 1400 | 3.19 |
01:28 ET | 15300 | 3.185 |
01:30 ET | 25168 | 3.175 |
01:32 ET | 6311 | 3.18 |
01:33 ET | 12100 | 3.1739 |
01:35 ET | 11227 | 3.1501 |
01:37 ET | 29415 | 3.16 |
01:39 ET | 8200 | 3.164 |
01:42 ET | 5002 | 3.165 |
01:44 ET | 1379 | 3.165 |
01:46 ET | 13530 | 3.16 |
01:48 ET | 2740 | 3.165 |
01:50 ET | 21681 | 3.16 |
01:51 ET | 8626 | 3.14 |
01:53 ET | 817 | 3.14 |
01:55 ET | 1600 | 3.145 |
01:57 ET | 10520 | 3.135 |
02:00 ET | 6510 | 3.135 |
02:02 ET | 500 | 3.135 |
02:04 ET | 700 | 3.135 |
02:06 ET | 900 | 3.135 |
02:08 ET | 3889 | 3.135 |
02:09 ET | 48505 | 3.135 |
02:11 ET | 3790 | 3.13 |
02:13 ET | 2000 | 3.135 |
02:15 ET | 1100 | 3.135 |
02:18 ET | 700 | 3.135 |
02:20 ET | 2825 | 3.14 |
02:22 ET | 20429 | 3.15 |
02:24 ET | 57975 | 3.125 |
02:26 ET | 5715 | 3.135 |
02:27 ET | 1002 | 3.13 |
02:29 ET | 1000 | 3.135 |
02:31 ET | 4723 | 3.135 |
02:33 ET | 25094 | 3.14 |
02:36 ET | 24393 | 3.14 |
02:38 ET | 5173 | 3.14 |
02:40 ET | 7860 | 3.135 |
02:42 ET | 16484 | 3.15 |
02:44 ET | 4415 | 3.145 |
02:45 ET | 700 | 3.145 |
02:47 ET | 1500 | 3.14 |
02:49 ET | 32566 | 3.135 |
02:51 ET | 1200 | 3.135 |
02:54 ET | 3108 | 3.135 |
02:56 ET | 34699 | 3.105 |
02:58 ET | 2400 | 3.1 |
03:00 ET | 16981 | 3.09 |
03:02 ET | 15400 | 3.075 |
03:03 ET | 52602 | 3.045 |
03:05 ET | 57564 | 3.05 |
03:07 ET | 20642 | 3.045 |
03:09 ET | 1540 | 3.045 |
03:12 ET | 2500 | 3.045 |
03:14 ET | 7070 | 3.05 |
03:16 ET | 25395 | 3.045 |
03:18 ET | 4155 | 3.045 |
03:20 ET | 6400 | 3.04 |
03:21 ET | 1580 | 3.045 |
03:23 ET | 23079 | 3.04 |
03:25 ET | 1335 | 3.045 |
03:27 ET | 3673 | 3.045 |
03:30 ET | 13727 | 3.045 |
03:32 ET | 42026 | 3.04 |
03:34 ET | 9110 | 3.035 |
03:36 ET | 21968 | 3.04 |
03:38 ET | 11651 | 3.035 |
03:39 ET | 27691 | 3.04 |
03:41 ET | 3536 | 3.045 |
03:43 ET | 20633 | 3.055 |
03:45 ET | 35190 | 3.05 |
03:48 ET | 121510 | 2.985 |
03:50 ET | 13881 | 2.985 |
03:52 ET | 47737 | 3.035 |
03:54 ET | 27550 | 3.035 |
03:56 ET | 142313 | 2.945 |
03:57 ET | 129928 | 2.955 |
03:59 ET | 186797 | 2.92 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 721.7M | -9.3x | --- |
Hillevax Inc | 719.0M | -4.4x | --- |
ProKidney Corp | 696.5M | -4.3x | --- |
Praxis Precision Medicines Inc | 707.6M | -2.6x | --- |
CARGO Therapeutics Inc | 752.8M | -5.6x | --- |
SS Innovations International Inc | 725.6M | -31.0x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $721.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 247.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.40 |
EPS | $-0.31 |
Book Value | $2.76 |
P/E Ratio | -9.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.